Guest

Cory S. Krebs, CFA CooksonPeirce

President and Chief Executive Officer

Company

CooksonPeirce

Website

https://cooksonpeirce.com/

AUM

Over $3B AUM

About Cory

Cory S. Krebs, CFA

President and Chief Executive Officer

As president and chief executive officer for CooksonPeirce, Cory Krebs is tasked with defining corporate strategy and executing the firm’s business plan. Cory is also a member of the firm’s portfolio management team, tasked with the administration of all CooksonPeirce investment strategies, including the Catalyst Dynamic Alpha Fund.

Prior to joining CooksonPeirce in 2003, Cory spent five years with Laurel Capital Advisors, an investment subsidiary of Mellon Financial, where he was responsible for all aspects of block order trading, participated in new product development, and assisted in the investment manager due diligence process. Before that, he served in a variety of positions at Federated Investors and American Express Financial Advisors.

Cory earned a B.A. in economics and an M.B.A. from the University of Pittsburgh. He also attained the designation of Chartered Financial Analyst from the CFA Institute. He is a member of the CFA Institute and the CFA Society of Pittsburgh. He is also a member of the Pittsburgh Society of Investment Professionals, where he has served on the board of directors and as president of the organization.

A proud honors graduate, Cory is a lifetime member of the University of Pittsburgh Alumni Association and the Panther Club. He lives in the South Hills with his wife and three school-aged children.

About CooksonPeirce

CooksonPeirce, registered in 1984, serves 47 states with a licensed staff of 10 advisors. Headquartered in Pittsburgh, PA, with satellite offices in Ohio, South Carolina, and Florida, CooksonPeirce manages over $3 billion and provides investment advisory services for more than 1,200 clients.

Important Disclosures

Investing involves risk, including possible loss of principal. Investment decisions are subject to market, currency, economic, and business risks and will not always be profitable. There is no guarantee that risk can be successfully mitigated or otherwise avoided.

Nothing herein is an offer to buy or a suggestion to sell securities. Statements using "if," "may," "can," "should," or "will" may be forward looking and are not intended as an opinion, projection, or estimate regarding the market, CooksonPeirce, or its products.

AUM of $3 billion as of June 30, 2026, subject to change.

CooksonPeirce & Co., Inc. is an SEC registered investment adviser. Registration does not imply a certain level of skill or training. See Form ADV at adviserinfo.sec.gov.

Guest Full Name: Dr. David-Alexandre (“DA”) C. Gros, MD

CEO

DA’s Bio:

Dr. Gros has served as Chief Executive Officer and a member of the Board of Directors of Eledon Pharmaceuticals, Inc. since September 2020. He joined Eledon Pharmaceuticals from Imbria Pharmaceuticals Inc., where he served as Co-Founder, Chief Executive Officer and

Chairman of the Board of Directors.

Prior to Imbria, Dr. Gros was President and Chief Operating Officer of Neurocrine Biosciences, Inc., Chief Business and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., and Chief Strategy Officer of Sanofi, S.A. Before joining Sanofi, Dr. Gros held leadership positions in healthcare investment banking at Centerview Partners, LLC, and Merrill Lynch, Pierce, Fenner & Smith Inc., and in healthcare consulting at McKinsey & Company.

He previously served on the Board of Directors of Eliem Therapeutics, Inc., a biotechnology company which he co-founded, and is currently the Executive Chairman of Saint Jean Groupe, S.A., a leading French manufacturer of pasta products since 1935.

Dr. Gros earned his Doctor of Medicine from The Johns Hopkins University School of Medicine, a Master of Business Administration from Harvard Business School, and a Bachelor of Arts from Dartmouth College.

Company: Eledon Pharmaceuticals, Inc.

Ticker: ELDN

Website: https://eledon.com/

About the Company:

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California.

This CEO Is Helping Netflix & Paramount + Stream Videos Faster & Better. Meet Mr. Sharon Carmel, CEO of Beamr $BMR

Guest: Mr. Sharon Carmel, CEO of Beamr $BMR

Guest Bio:

Mr. Carmel is founder and CEO of Beamr. He is a serial entrepreneur with a proven track record in the video and software space. In 1994, Mr. Carmel co-founded Emblaze (LON: BLZ), which developed the first video chips for Samsung Mobile. The company went public in 1996, and in 2000 reached a peak market cap of ~$7 billion. In 2002, Mr. Carmel founded his second start-up, BelnSync, which developed P2P synchronization and online backup technologies, and was acquired in 2008 by Phoenix Technologies (Nasdaq: PTEC).

Company

Beamr (Nasdaq: BMR), is a world leader in content-adaptive video compression, trusted by top media companies including Netflix and Paramount. Beamr’s perceptual optimization technology (CABR) is backed by 53 patents and a winner of Emmy® Award for Technology and Engineering. The innovative technology reduces video file sizes by up to 50% while preserving quality and enabling AI-powered enhancements.

Beamr powers efficient video workflows across high-growth markets, such as media and entertainment, user-generated content, machine learning, and autonomous vehicles. Its flexible deployment options include on-premises, private or public cloud, with convenient availability for Amazon Web Services (AWS) and Oracle Cloud Infrastructure (OCI) customers.

Website: https://beamr.com/

This CEO Wants To Help Your Nerves Heal Faster. Meet Adam Rogers CEO NervGen – NGEN

Guest

Adam Rogers, MD, Chair, President & Chief Executive Officer at NervGen

Adam’s BIO:

Adam H. Rogers, MD, is the President and Chief Executive Officer of NervGen Pharma and has served as Chairman of the Company’s Board of Directors since July 2025. Dr. Rogers has more than fifteen years of experience advancing novel therapies for diseases with significant unmet medical need.

He is the Principal of Boston-based PFP Biosciences Holdings and previously co-founded Hemera Biosciences in 2010, a clinical-stage biotechnology company developing a one-time investigational gene therapy administered via outpatient intravitreal injection to preserve vision in patients with geographic atrophy, a late-stage and severe form of age-related macular degeneration.

He served as Hemera’s Chief Executive Officer from 2017 until December 2020, when the rights to its lead program were acquired by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. Earlier in his career, Dr. Rogers served as an Assistant Professor of Ophthalmology at the New England Eye Center at Tufts Medical Center and has authored numerous peer-reviewed publications.

Dr. Rogers is a board-certified ophthalmologist specializing in diseases and surgery of the retina and vitreous and holds an MD from Emory University School of Medicine.

Company Bio

NervGen Pharma (NASDAQ: NGEN) is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions.

The Company’s mission is to transform the lives of individuals living with SCI by enabling the nervous system to repair itself. NervGen’s lead therapeutic candidate, NVG-291, is a subcutaneously administered, neuroreparative peptide designed to target the inhibitory CSPG-PTPσ pathway. NVG-291 is the first pharmacologic candidate to improve function, independence, and quality of life in chronic tetraplegia, as demonstrated in the Phase 1b/2a CONNECT SCI study. NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency for the treatment of SCI.

Through NVG-291 and the Company’s next-generation candidate, NVG-300, NervGen is pursuing a pharmacologic approach to transform the treatment paradigm for neurotraumatic and neurologic conditions with significant unmet medical need. For more information, visit www.nervgen.com and follow NervGen on X and LinkedIn.

Bio:

Sean Duffy is the Co-founder and CEO of Omada Health, a between-visit care provider that addresses cardiometabolic conditions like diabetes, hypertension, prediabetes, and obesity, as well as musculoskeletal issues.

He has dedicated his professional life to bridging technology, design, and care delivery to transform care experiences for patients. As a former MD/MBA candidate at Harvard, he also holds a BS in neuroscience from Columbia University.

He has written extensively about digital health and the future of healthcare in The New England Journal of Medicine, The Wall Street Journal, Forbes, and TechCrunch, among other publications. Prior to Omada, Sean worked at both Google and IDEO.

Company:

Omada Health (Nasdaq: OMDA) is reverse engineering the way healthcare is delivered in America, putting the space between doctor visits–where health is won or lost–at the center of care.

Today's healthcare system poorly serves chronic conditions that require ongoing support outside of the exam room, like obesity, diabetes, hypertension, cholesterol, and musculoskeletal conditions. Omada’s virtual-first model combines human-led care teams, connected devices, and AI-enabled technology to deliver personalized care at scale, including support for GLP-1 therapy.

Omada has served more than two million members since launch across 2,000+ employers, health plans, pharmacy benefit managers, and health systems. Learn more at omadahealth.com.

This CEO Is Helping Companies Advertise On TV, In A Better Way – Meet Mark Douglas Mountain- MNTN

* Mark Douglas | MNTN President & CEO

* Mountain

* https://mountain.com/

* NYSE: MNTN

Bio: https://mountain.com/about/

About Mark

Mark oversees the direction of MNTN with his 20 years of product development experience gained through repeated success in helping fast-growth companies transition into emerging markets. He started at Oracle. Shortly after, Mark founded a series of successful startups resulting in IPOs and acquisitions. He was the VP of Technology at eHarmony where he built personality-matching technology. More recently, Mark built new technology for Rubicon Project as the VP of Engineering.

About MNTN:

MNTN (NYSE: MNTN) is the Hardest Working Software in Television™, bringing unrivaled performance and simplicity to Connected TV advertising. Our self-serve technology makes running TV ads as easy as search and social and helps brands drive measurable conversions, revenue, site visits, and more. MNTN was named one of Fast Company’s Most Innovative Companies and Next Big Things in Tech, and was recently featured on the cover of INC’s Best in Business Issue. For more information, please visit https://mntn.com/.

David Stamler, M.D., Chief Executive Officer AlterityTherapeutics

Alterity Therapeutics (NASDAQ: ATHE & ASX: ATH)

www.alteritytx.com

David Stamler, M.D., Chief Executive Officer

David Stamler, M.D. is Chief Executive Officer and a Managing Director, and previously served as Alterity's Chief Medical Officer and Senior Vice President, Clinical Development. Dr Stamler has extensive drug development expertise spanning early-stage research through late-stage clinical trials, with three FDA drug approvals in neurology.

Prior to joining Alterity, Dr. Stamler served as the Vice President, Clinical Development and Therapeutic Head for Movement Disorders at Teva Pharmaceutical Industries after Teva acquired Auspex Pharmaceuticals where he was Chief Medical Officer.

Prior to Auspex, he served as Senior Vice President and Chief Medical Officer at XenoPort, Inc., and Head of Drug Development at Prestwick Pharmaceuticals, Inc. Before Prestwick, Dr. Stamler worked at Fujisawa Pharmaceutical Co. and its subsidiaries in various leadership roles, including Vice President, Research and Development, Medical Sciences at Fujisawa Healthcare, Inc., and as Vice President, Clinical Research Center at Fujisawa Research Institute of America. Dr. Stamler began his career at Abbott Laboratories where he served in various positions including Director of Clinical Research, Pharmaceutical Products for the International Division.

Dr. Stamler received an M.D. from the University of Chicago—The Pritzker School of Medicine and a B.A. in Biology from the University of Chicago.

This CEO Is Advancing Neuroscience, Reducing Pain, & Treating Epilepsy – Meet Dave Rosa, CEO, NeuroOne Medical Technologies $NMTC

Guest:

Dave Rosa, CEO, NeuroOne Medical Technologies $NMTC

Dave's Bio

Dave Rosa is an entrepreneur with three decades of experience in the medical device industry spanning a variety of technologies and products. In addition to CEO roles with early-stage medical device companies, Mr. Rosa’s background also includes senior roles with C.R. Bard Inc., Boston Scientific Inc., and St. Jude Medical, where his responsibilities included marketing, product development and business development. He has been named as an inventor on multiple medical device patents, serves on seven corporate boards, and has raised $200M in the capital markets. Mr. Rosa holds an MBA from Duquesne University and a BS in Commerce and Engineering from Drexel University.

Mr. Rosa currently serves as the President and CEO of NeuroOne (Nasdaq: NMTC), a medical technology company that develops high-definition, minimally invasive diagnostic and therapeutic devices based on its unique thin film electrode technology.

NeuroOne, Nasdaq: NMTC

Website

https://nmtc1.com

Company Bio

NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders. NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo(R) Cortical Electrodes, Evo(R) sEEG Electrodes, OneRF(R) Ablation System (for brain), and OneRF(R) Trigeminal Nerve Ablation System. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering combination diagnostic and therapeutic functions. The Company is engaged in research and development for drug delivery and spinal cord stimulation programs.

A Different Kind of Police Tool & A Different Kind of Investment Story. Meet Scot Cohen CEO $WRAP

Guest

Scot Cohen: CEO & Executive Chairman, Wrap Technologies, Inc.

Scot's Bio

Co-founder and largest shareholder of Wrap Technologies, Scot Cohen has led the company's strategy and financing since its 2016 founding. He brings 30+ years in asset management and capital markets, having co-founded Iroquois Capital, a New York hedge fund managing approximately $300M.

Wrap Technologies, Inc.

Website: wrap.com

Ticker: Nasdaq: WRAP

Company Bio

Wrap Technologies is a global public-safety technology company building non-lethal response solutions for law enforcement, security, and defense. The company is rapidly expanding into drone-based public safety, having launched DFR-X, the first U.S. commercially available non-lethal Drone First Responder interdiction system, alongside its MERLIN-Interdictor and MERLIN-1 counter-drone (C-UAS) payloads, which can deploy non-lethal force from the air and entangle hostile drones mid-flight.

This CEO Makes Electric Trucks For UPS, FedEx, & Others – Meet Dakota Semler CEO XOS Trucks -$XOS

Guest Dakota Semler, Chief Executive Officer

Dakota Semler is the Chief Executive Officer of Xos, a Los Angeles-based technology company, fleet services provider, and manufacturer of Class 5 through Class 8 battery-electric vehicles.

Xos’ mission is to decarbonize commercial transportation with the most durable trucking technology available. Dakota has been in the transportation and trucking industry for more than a decade and grew up working on his family’s fleet business.

He came up with the idea for Xos to solve the exact challenge he faced as a fleet operator: to create a cost-effective, durable, and reliable electric vehicle that achieves the same, or better, performance benchmarks of an existing diesel vehicle—without compromising the air we breathe.

Since 2018, Xos has deployed hundreds of its 100% battery-electric vehicles with leading fleets within parcel delivery, cash-in-transit, beverage distribution, and linen and textile services. Dakota was named in the Forbes 30 Under 30 in Manufacturing & Industry In 2019.

Company information

Xos, Inc.

www.xostrucks.com.

Ticker: NASDAQ: XOS

Company Bio:

Xos, Inc. (NASDAQ: XOS) is a leading technology company and fleet services provider specializing in battery-electric fleet solutions and mobile energy storage infrastructure. The Company's mobile and stationary energy storage systems are purpose-built for the demanding requirements of commercial and municipal fleet operations.

They deliver reliable, cost-effective charging without costly utility upgrades or grid improvements, supported by proprietary fleet management software and fully electric commercial vehicles for seamless operations.

Founded in 2016 by Dakota Semler and Giordano Sordoni, Xos was built on a simple premise: the transition from diesel to electric should be as seamless as possible for fleet operators. The Company's integrated portfolio is anchored by its energy storage platform, complemented by fully electric commercial vehicles and powertrain technology for OEM partners, offering fleet operators a comprehensive path to zero-emission operations.

Xos has served commercial and municipal operators since 2018 and is trusted by industry leaders including Waymo, Caltrans, FedEx ISPs, UPS, Loomis, and Cintas, among others. Headquartered in Los Angeles, California, with production operations in Byrdstown, Tennessee, the Company went public in August 2021 and trades on NASDAQ under the ticker symbol XOS. For more information, visit www.xostrucks.com.